| « Previous month | Next month » |
Administrators are now trying to sell Jaycare, a UK custom manufacturer and supplier of rigid plastic packaging, medical devices and technical componentry to the pharma and healthcare industries, which has gone bust.
At this week's Informex show in New Orleans, experts at a packed out session discussed the potential of up-and-coming continuous processing technologies and posed the question: is batch processing yesterday's technology?
UK firm Prosonix has teamed up with defence specialist Rafael, exclusively licensing the firm's ultrasonic particle engineering technology to bolster its position in the process chemistry market.
US contract manufacturer Catalent Pharma Solutions has leveraged its partnership with Secure Symbology (SSI) for track and trace barcode technology to help biopharmaceutical company Biogen Idec comply with California's pending ePedigree law.
Allos Therapeutics, Inovio Biomedical, Cortegra and Genetix have all had people on the move in the world of pharmaceutical manufacturing.
A new, non-invasive device for monitoring oxygen content in packaging and other enclosed containers has been launched by US optical sensing specialist Ocean Optics.
US researchers have developed a method of treating waste water that is effective in stripping out hormonal compounds thought to arise from the use and manufacturing of contraceptives and other pharmaceutical and industrial products.
A non-destructive method of carrying out a series of tests on solid dosage forms, developed by UK firm Teraview, can be carried out in real time on the production line and could be used in continuous processing systems, according to a new study.
Merck & Co has expanded its licensing agreement with SurModics in a further endorsement of the latter's I-vation drug delivery system for eye diseases.
660 Pfizer employees are the latest casualties of the drug giant's failed bid to capture the diabetes market with its once-touted blockbuster, Exubera.
In any laboratory, or indeed in any pharmaceutical manufacturing facility, one of the major expenses will be solvents. And just like the price of petrol and diesel it just keeps going up and up. Huw Kidwell examines how a new recycling approach could keep costs down and help protect the environment to boot.
Unexpected contract downturns have resulted in Catalent Pharma Solutions having to lay off 100 workers at its soft gelatin capsules facility in St Petersburg, Florida.
In the world of chemistry the majority of reactions are well known and have been around for a very long time producing similar compounds. It is not very often that a completely new reaction methodology comes along which can turn something like chiral chemistry on its head. However this is the case with a series of rhodium (II) based chiral catalysts developed by US researchers.
Wyeth is the latest big pharma firm to warn that major job cuts are on the cards, amidst a series of drug approval setbacks and generic erosion on profits.
MiddleBrook Pharmaceuticals secured a crucial endorsement for its Pulsys oral drug delivery system last week when the US Food and Drug Administration (FDA) approved the company's lead pipeline product, Moxatag, as a once-daily treatment for pharyngitis/tonsillitis in adults and adolescents.
A new enterprise in the United Arab Emirates (UAE) is establishing itself as the region's first pharmaceutical-focused third party logistics (3PL) provider.
The small but fast-growing biopharmaceutical ingredients (BPI) business of Denmark's Novozymes, the leading manufacturer of industrial enzymes worldwide, delivered a strong performance in 2007, with sales rising 67 per cent despite a sharp decline in the fourth quarter.
Another sharp decline in biomedical production saw overall manufacturing output in Singapore fall for the second month running in December, prompting fears that the heavily trade-reliant economy could buckle under a looming US recession.
With the price of crude oil going up almost every day it is no surprise that this has a knock-on effect to the price of raw materials for the pharmaceutical and chemical industries. But DSM and Roquette have developed a process that could avoid the reliance on crude oil for succinic acid, a simple but very useful pharmaceutical starting material, promising cheaper and greener supplies.
KBI Biopharma, Helix BioMedix and Azopharma have all recently announced new contract manufacturing news.
Nabi Biopharmaceuticals this week announced that is considering a possible sale or merger of the company, with 'multiple entities' apparently interested in the business.
Codexis, NanoInk, HepaLife, Nabi Biopharmaceuticals and Calibrant Biosystems have all had people on the move in the world of pharmaceutical manufacturing.
Lonza has revealed a profit hike for the full year of 2007, reflecting the fruit of its "revised growth strategies" across its business units, said the firm, which also announced its "innovations" for future growth and the signing of a new Sanofi Pasteur deal.
Australia-based Invetech has committed itself to tackling the US market, opening up its first facility in the country - home of the world's largest drug industry.
Israeli generics behemoth Teva is following the market and banking on the promise of biologics with its purchase of Human Genome Sciences biotech spin-off, CoGenesys.
French firm Novasep has significantly upped its capacity with a new high potency active pharmaceutical ingredient (HPAPI) plant at its facility in Le Mans, France.
Bosch Packaging has opened a new manufacturing facility in Goa, India, to cater to its growing customer base in the booming emerging market and increase sourcing for its European headquarters.
Bristol-Myers Squibb (BMS) has revealed plans to close another site in Puerto Rico in its latest cost-cutting move.
Novartis has announced the US approval of its first-in-class blood pressure med Tekturna (aliskiren) combined with a diuretic in a single-tablet formulation.
Canadian vaccine specialist ImmunoVaccine Technologies (IVT) has scored a multi-million dollar grant to go towards developing its potent immune enhancement systems.
Roche has announced major investments at three of its European sites, continuing its drive to strengthen its position in the biopharmaceutical market.
California-based Medegen has opened a new facility in Mexico to meet the 'heightened demand' for outsourced contract manufacturing.
Icelandic generics firm Actavis is the proud new owner of Pfizer's manufacturing facility in Nerviano, Italy.
The US Food and Drug Administration (FDA) is considering establishing a presence in India, amidst the country's growing ties with the US pharma industry.
Outsourcing will be seen as being "instrumental" in the eyes of healthcare and biopharma firms this year as the focus on cost reduction continues to increase, according to a new report.
In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry.
Neurocrine, Mersana Therapeutics, ISPE and Nastech have all had people on the move in the world of pharmaceutical manufacturing.
The European Commission has launched an investigation into the entire European pharmaceutical sector, with surprise raids on a number of manufacturers in a bid to unearth any evidence of foul-play hampering the launch of new medicines on the market.
Processing specialist Sartorius Stedim Biotech today announced a cooperation and supply deal with systems manufacturing firm Paul Mueller Company for the US market, with a production facility in Pennsylvania set to close as a result.
Wyeth's manufacturing facility in Rouses Point, New York, has been spared the scrap heap, with yesterday's announcement that new pharma player Akrimax has bought up the beleaguered site.
AMRI, Pharmaceutics International, Celitrion and Gland Pharma have all recently generated new contract manufacturing news.
SAFC is still on its expansion drive, with yet another multi-million dollar investment announced this week, this time at the company's niche biologics plant in Carlsbad, California.
German firm Artes announced a new collaboration with Rhein Minapharm Biogenetics to develop three therapeutic proteins.
Mere months after Pfizer's high profile exit from the inhaled insulin market in the wake of Exubera's much publicised market failure, Novo Nordisk announced late last night that it, too, has decided to halt development of its inhaled insulin product.
UK separation technology specialists Whatman has confirmed it has received a number of preliminary approaches for the firm, sending its shares rocketing up.
Chemical and intermediates firm Lanxess has announced that its subsidiary Saltigo is the proud new owner of a site in Washington in the US, formerly used by Eli Lilly subsidiary, ICOS.
A major grant has been awarded to a UK consortium working to develop predictive manufacturing tools for cell-based cancer vaccines.
Cambrex' Swedish arm has agreed to purchase ProSyntest, an Estonian active pharmaceutical ingredients (API) research and development company.
Thousands of rodents lives will be saved each year after a specific animal test is being scrapped following a review by 18 pharmaceutical companies.
Diagnostics firm bioMérieux has announced plans to shift activities at its facility in the Netherlands to France, shutting down the Dutch site as it continues to haemorrhage cash.
The world's generics titan, Teva, has reportedly earmarked over $1bn to fuel an ambitious plan to broaden its presence in India.
Novartis has been keen to shout about data published this week in the Journal of the American Medical Association (JAMA) that backs up claims that it has developed the first vaccine to protect infants against the most common meningitis subgroups.
BioAlliance Pharma has gained marketing authorisation for its novel muco-adhesive antifungal tablet in the UK and Denmark, triggering a €2.5m payment and marching on with the drug's launch across Europe.
Roche today announced a handful of new charitable technology transfer agreements with manufacturers in Africa and Asia, allowing local production of generic HIV drugs.
Draxis, Intertech Bio, Relypsa, Ikaria Holdings and BioReliance have all had people on the move in the world of pharmaceutical manufacturing.
Eli Lilly's once-a-day version of its erectile dysfunction (ED) treatment Cialis (tadalafil) has finally got the go ahead from US regulators, six months after approval in the EU.
Millipore has announced the first fruit of its collaboration with testing specialist Gen-Probe, with the launch of a new contaminant detection system for biopharmaceutical manufacturers.
Pharmacies in the UK would indeed be foolish to ignore new restrictions on nasal decongestants that will become law as of April 1, 2008.
Drug delivery specialist Antares Pharma has landed its fourth deal with Israeli generics behemoth Teva, this time to develop a novel pen injector for two Teva products.
Pfizer, Hyaluron Contract Manufacturing and DSM have all recently generated new contract manufacturing news.
A starch-based film coating for nutraceuticals which can be tailored to manufacturer's needs is being developed through a strategic partnership by Roquette and Biogrund.
Dutch firm Crucell last week announced that it has entered into an agreement with vaccine specialist Sanofi Pasteur for its next generation rabies antibody cocktail.
A recent report has detailed the challenges facing the pharma industry as the generic flood gates open, with the constant advice to start planning early still apparently not heeded by a bewildering number of firms.
Although India 'has carved out a significant portion of the world pharma pie', an enormous change in mindset is needed if the country is to become a global pharmaceutical hub, according to a new report from KPMG.
The pharma industry spends almost twice as much promoting its drugs as it does trying to develop them, according to a new study.
A group of US researchers have developed a new computer model to study and design miniature biosensors, which could help life scientists perfect lab-on-a-chip technology.
Despite a two month extension of the PDUFA date by the US Food and Drug Administration (FDA), Sciele and SkyePharma this week announced the approval of their controlled release formulation of high blood pressure drug Sular (nisoldipine).
Several pharmaceutical packaging players completed deals in time for the holidays, with Schott, Gerresheimer and Alcoa all announcing developments in the closing days of 2007.
Merck & Co has handed the reins of one of its US active pharmaceutical ingredient (API) manufacturing facilities over to new a owner, who has also secured a lucrative contract manufacturing deal with the drug giant.
A team of US researchers have uncovered a cocktail of three drugs that could be effective at treating every patient with a particular type of brain cancer that typically has a dismal prognosis.
Italy's Fine Foods has purchased a domestic contract manufacturer operating in the pharmaceutical arena, extending its presence in this industry.
While GSK, AstraZeneca and Eli Lilly have hit the headlines in the UK Serious Fraud Office's (SFO) investigation into illegal bribes paid to Saddam Hussein's Iraqi regime, many more pharma firms are on the organisation's hit list.
Applied Biosystems, Pharmos, Pearl Therapeutics, Pacira Pharmaceuticals and Covance have all had people on the move in the world of pharmaceutical manufacturing.
| « Previous month | Next month » |